Bigbear Pharmaceutical·Medication Guide

• IDHIFA (enasidenib) Drug Guide

  On August 1, 2017, the U.S. Food and Drug Administration (FDA) officially approved IDHIFA (enasidenib) for the treatment of adult patients with relaps···【Read More】

  Update: 2026-03-24Source: Haiou HealthViews: 171

• Which other drugs may interact with entrectinib?

  Certain medications should not be used together, as this can compromise safety. Some drugs can alter the blood concentrations of entrectinib, which ma···【Read More】

  Update: 2026-03-24Source: Haiou HealthViews: 182

• What should I avoid while taking entrectinib?

  Avoid driving, operating heavy machinery, or engaging in any potentially dangerous activities until you know how entrectinib affects you. Dizziness or···【Read More】

  Update: 2026-03-24Source: Haiou HealthViews: 181

• What should I do in case of an overdose of Entrectinib?

  Seek immediate medical attention or contact the Poison Control Center right away.【Read More】

  Update: 2026-03-24Source: Haiou HealthViews: 182

• What should I do if I miss a dose of Entrectinib?

  Take the medication as soon as you remember. If your next scheduled dose is due within 12 hours, skip the missed dose and continue with your regular d···【Read More】

  Update: 2026-03-24Source: Haiou HealthViews: 196

• Indications for entrectinib:

  Indications for entrectinib:1. For the treatment of adult patients with ROS1-positive metastatic non-small cell lung cancer (NSCLC) confirmed by an FD···【Read More】

  Update: 2026-03-24Source: Haiou HealthViews: 190

• Side Effects of Entrectinib

  Patients should be aware of adverse reactions occurring during entrectinib use. If symptoms are severe, consult a doctor promptly for dosage adjustmen···【Read More】

  Update: 2026-03-24Source: Haiou HealthViews: 189

• Entrectinib Dosage Guidelines

  Due to significant individual differences among cancer patients, including tumor molecular characteristics, physical function, and comorbidities, drug···【Read More】

  Update: 2026-03-24Source: Haiou HealthViews: 191

• The European Commission (EC) has approved Rozlytrek (entrectinib) for the treatment of NTRK fusion-p

  Roche recently announced that the EC has conditionally approved the targeted anticancer drug Rozlytrek for the treatment of pediatric and adult patien···【Read More】

  Update: 2026-03-24Source: Haiou HealthViews: 236

• How effective is Rozlytrek (entrectinib) in treating NTRK fusion-positive solid tumors and ROS1-posi

  The European Commission (EC) has approved the targeted anticancer drug Rozlytrek (entrectinib) for the treatment of pediatric and adult patients aged ···【Read More】

  Update: 2026-03-24Source: Haiou HealthViews: 163

• FDA Approves FoundationOneCDx as Companion Diagnostic for Two Indications of Rozlytrek (entrectinib)

  On June 9, 2022, Foundation Medicine announced that the U.S. Food and Drug Administration (FDA) has approved FoundationOneCDx as a companion diagnosti···【Read More】

  Update: 2026-03-24Source: Haiou HealthViews: 164

• Rozlytrek Expands Age Range to Pediatric Patients with NTRK Gene Fusion-Positive Solid Tumors and Re

  The U.S. Food and Drug Administration (FDA) announced on October 20 that it has granted accelerated approval to Rozlytrek (entrectinib) for the treatm···【Read More】

  Update: 2026-03-24Source: Haiou HealthViews: 167

• Crizotinib Indications

  Crizotinib has a proven therapeutic effect on ALK-related diseases, effectively controlling tumor progression and improving patient clinical outcomes.···【Read More】

  Update: 2026-03-24Source: Haiou HealthViews: 197

• Crizotinib Side Effects

  Crizotinib may cause side effects that do not require medical intervention and may gradually disappear as the body adapts to the drug during treatment···【Read More】

  Update: 2026-03-24Source: Haiou HealthViews: 192

• ​Crizotinib Dosage Guidelines

  Crizotinib has different specific usages in adults and children for different indications. Users are advised to consult their doctor before using criz···【Read More】

  Update: 2026-03-24Source: Haiou HealthViews: 192